Cantargia's aim is to develop specific antibody against proteins on the surface of leukaemia stem cells and eventually also against other solid tumour cells.

Cantargia AB’s focus is on the development of a discovery made by Professor Thoas Fioretos and Dr Marcus Järås from Lund University. Their research showed that leukaemia stem cells express a protein on the surface called IL1RAP, which is not expressed to a large extent on normal cells. In collaboration with the founders, Cantargia has developed specific antibodies against IL1RAP. Cantargia’s objective is to develop a new drug that can become an important part of future cancer treatment.